Skip to main content

Lupus clinical trials at UCSF
4 in progress, 4 open to new patients

  • A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

    open to eligible people ages 18 years and up

    The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.

    Fresno, California and other locations

  • Autologous Polyclonal Tregs for Lupus

    open to eligible people ages 18 years to 60 years

    The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus. Targeting cutaneous disease offers the ability to control background therapy, readily detect clinical effects, and perform research analyses not only in blood but also skin. Safety, disease activity, and mechanism of Tregs will be evaluated. The intent is to support dose selection for a future larger efficacy trial in lupus.

    San Francisco, California

  • Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

    open to eligible people ages 18 years to 70 years

    This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

    San Francisco, California and other locations

  • Rituximab and Belimumab for Lupus Nephritis

    open to eligible people ages 18 years and up

    In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.

    San Francisco, California and other locations